Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theralase Technologies Inc. V.TLT

Alternate Symbol(s):  TLTFF

Healthcare Medical Devices
Theralase Technologies Inc. is a Canada-based clinical-stage pharmaceutical company. The Company is engaged in the research and development of light activated compounds and their associated drug formulations. The Company operates through two divisions: Anti-Cancer Therapy (ACT) and Cool Laser Therapy (CLT). The Anti-Cancer Therapy division develops patented, and patent pending drugs, called Photo Dynamic Compounds (PDCs) and activates them with patent pending laser technology to destroy specifically targeted cancers, bacteria and viruses. The CLT division is responsible for the Company’s medical laser business. The Cool Laser Therapy division designs, develops, manufactures and markets super-pulsed laser technology indicated for the healing of chronic knee pain. The technology has been used off-label for healing numerous nerve, muscle and joint conditions. The Company develops products both internally and using the assistance of specialist external resources.


TSXV:TLT - Post by User

Theralase Technologies Inc. > Commercialization phase - Jan 2023 to December 2025
<< Previous
 Bullboard Posts
Next >>
User Avatar Image
(548)
•••
Comment by Rumpl3StiltSkinon May 05, 2022 10:40am
139 Views
Post# 34658515

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Commercialization phase - Jan 2023 to December 2025

RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:RE:Commercialization phase - Jan 2023 to December 2025
jmm1228 wrote:

How will TLT carry on the establishment of a full scale market ing/manufacturing/distribution operation
with the assets presently at hand? 

What is the best way to establish such expediently given the current lack of these vital capabilities and the long dwell time to establish. The learning curve is steep!

What entities believe they are best positioned to handle the matter?

Stay tuned, something will happen, the status quo won't carry this off.


 



Will it be a Big Pharma deal? A Medium/Big Biotech? Or a Covid deal with Public Health Canada?? Any improvements on ANY front should lead to one of these...

<< Previous
 Bullboard Posts
Next >>
Dealroom for high-potential pre-IPO opportunities